Grant: Discovery Grants Program - Individual
Simon Fraser University
$32,000.00
Biomarker sensors based on 2D materials for diagnostic applications
EF 2024-25
Résumé
Biomarkers are measurable indicators that help determine if a person may have or be at risk of developing a disease. They also help clinicians select a treatment option, monitor effectiveness of treatments, and can be used in identifying populations during drug development studies. The focus of the proposed research program is to develop new methods for sensing biomarkers of Alzheimer's disease and lung cancer using atomically thin nanomaterials called two-dimensional (2D) materials. The proposed research program has three objectives: 1) demonstrate detection of Alzheimer's disease protein biomarkers in blood samples; 2) demonstrate identification of volatile organic compound (VOC) biomarkers in breath samples; 3) integrate large-area scalable 2D materials into protein biomarker sensors.
The expected outcome of the Objective 1 is a new sensor technology that can detect Alzheimer's disease biomarker, glial fibrillary acidic protein (GFAP), at femtomolar concentrations and high specificity to facilitate detection in blood samples. The advantage of the proposed diagnostic tool is that it is rapid, simple-to-use, and is minimally invasive requiring less than 3 microliters of sample. In comparison, standard tests such as ELISA require at least 100 microliters of sample. The expected outcome of the Objective 2 is a new method to identify volatile organic compounds (VOCs) which are biomarkers for Alzheimer's disease (styrene and 2-butanone) and lung cancer (2-butanone and toluene) from breath samples at parts-per-billion concentrations. The advantage of the proposed diagnostic tool is that it is non-invasive and simple to use. The expected outcome of Objective 3 is new knowledge to integrate 2D materials prepare large-area scalable methods such as chemical vapour deposition (CVD) which are compatible with manufacturing processes.
Dementia is a growing health challenge that affects over 500,000 Canadians today, and a predicted over 900,000 by 2030 [6]. Alzheimer's disease (AD), the most common form of dementia, is correlated with evidence of protein misfolding in the brain. This process starts over a decade before clinical symptoms are noticed [7-9]. Therefore, it may be possible to diagnose this disease at an early stage when treatment strategies are most effective. Existing biomarker detection methods are expensive, time-consuming, and need to be sent to a lab for analysis, limiting availability to Canadians. There is a need for a simple, low-cost, and rapid test that can measure multiple biomarkers at once [10], which can help clinicians diagnose Alzheimer's disease and other diseases. The new diagnostic methods developed during this research program have the potential to help clinicians diagnose Alzheimer's disease and lung cancer by increasing the availability of screening tests for Canadians.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2023-05188
Name nom
Adachi, Michael
Department département
School of Engineering
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1510
Committee name en
Electrical and Computer Engineering
Committee name fr
Génie électrique et informatique
Area of application code
513
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Electrical and electronic machinery and equipment (including computer hardware)
Area of application fr
Machinerie et équipement électriques et électroniques (y compris matériel informatique)
Research subject code
2506
Research subject group en
Electrical and electronic engineering
Research subject group fr
Génie électrique et électronique
Research subject en
Electron devices
Research subject fr
Dispositifs électroniques
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Biomarker sensors based on 2D materials for diagnostic applications
Keywords
2d materials; nanomaterials; biomedical sensors; diagnostic sensors; nanofabrication; semiconductor devices; device fabrication; device architecture; protein biomarkers; volatile organic compounds
Application summary
Biomarkers are measurable indicators that help determine if a person may have or be at risk of developing a disease. They also help clinicians select a treatment option, monitor effectiveness of treatments, and can be used in identifying populations during drug development studies. The focus of the proposed research program is to develop new methods for sensing biomarkers of Alzheimer's disease and lung cancer using atomically thin nanomaterials called two-dimensional (2D) materials. The proposed research program has three objectives: 1) demonstrate detection of Alzheimer's disease protein biomarkers in blood samples; 2) demonstrate identification of volatile organic compound (VOC) biomarkers in breath samples; 3) integrate large-area scalable 2D materials into protein biomarker sensors.
The expected outcome of the Objective 1 is a new sensor technology that can detect Alzheimer's disease biomarker, glial fibrillary acidic protein (GFAP), at femtomolar concentrations and high specificity to facilitate detection in blood samples. The advantage of the proposed diagnostic tool is that it is rapid, simple-to-use, and is minimally invasive requiring less than 3 microliters of sample. In comparison, standard tests such as ELISA require at least 100 microliters of sample. The expected outcome of the Objective 2 is a new method to identify volatile organic compounds (VOCs) which are biomarkers for Alzheimer's disease (styrene and 2-butanone) and lung cancer (2-butanone and toluene) from breath samples at parts-per-billion concentrations. The advantage of the proposed diagnostic tool is that it is non-invasive and simple to use. The expected outcome of Objective 3 is new knowledge to integrate 2D materials prepare large-area scalable methods such as chemical vapour deposition (CVD) which are compatible with manufacturing processes.
Dementia is a growing health challenge that affects over 500,000 Canadians today, and a predicted over 900,000 by 2030 [6]. Alzheimer's disease (AD), the most common form of dementia, is correlated with evidence of protein misfolding in the brain. This process starts over a decade before clinical symptoms are noticed [7-9]. Therefore, it may be possible to diagnose this disease at an early stage when treatment strategies are most effective. Existing biomarker detection methods are expensive, time-consuming, and need to be sent to a lab for analysis, limiting availability to Canadians. There is a need for a simple, low-cost, and rapid test that can measure multiple biomarkers at once [10], which can help clinicians diagnose Alzheimer's disease and other diseases. The new diagnostic methods developed during this research program have the potential to help clinicians diagnose Alzheimer's disease and lung cancer by increasing the availability of screening tests for Canadians.